Prognosis in Patients with Non-Small Cell Lung Cancer Who Received Erlotinib Treatment and Subsequent Dose Reduction due to Skin Rash

Publisher： Karger

E-ISSN： 2296-5262|35|12|747-752

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.12, 2012-11, pp. : 747-752

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefit of Erlotinib in Patients with Non-Small-Cell Lung Cancer Is Related to Smoking Status, Gender, Skin Rash and Radiological Response but Not to Histology and Treatment Line

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 249-258

Karger

Access to resources Recommend Favorite

Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 78-84

Karger

Access to resources Recommend Favorite

Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice

By  

Oncology, Vol. 84, Iss. 5, 2013-02 ,pp. : 255-264

Karger

Access to resources Recommend Favorite

Erlotinib after Failure of Gefitinib Treatment of More Than 6 Months in Advanced Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 8-9

Karger

Access to resources Recommend Favorite